Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI Meeting
09 déc. 2024 07h00 HE
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact...
Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference
26 nov. 2024 16h05 HE
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update
12 nov. 2024 16h12 HE
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact...
Orchestra BioMed to Participate in Jefferies London Healthcare Conference
07 nov. 2024 08h00 HE
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
12 août 2024 16h20 HE
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact...
Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors
30 juil. 2024 08h00 HE
|
Orchestra BioMed Holdings, Inc.
John Mack brings over 30 years of diverse medical device and healthcare technology experience to the Orchestra BioMed Board of Directors Most recently, Mr. Mack served as Medtronic’s President of...
Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
04 juin 2024 08h00 HE
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
22 mai 2024 08h43 HE
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update
13 mai 2024 16h58 HE
|
Orchestra BioMed Holdings, Inc.
Company hosting in-person R&D day event, focused on atrioventricular interval modulation (“AVIM”) therapy, including the unmet need in hypertension, mechanism of action, clinical results and...
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
30 avr. 2024 08h30 HE
|
Orchestra BioMed Holdings, Inc.
Patent estate covering atrioventricular interval modulation (“AVIM”) therapy includes 37 issued U.S. patents and 73 patents outside the U.S. that collectively comprise over 1,800 claims related to the...